Cargando…

Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations

SIMPLE SUMMARY: Neoadjuvant chemotherapy followed by radical cystectomy is the recommended standard of care for muscle-invasive bladder cancer patients who are eligible for cisplatin. Achieving a pathologic complete response in radical cystectomy provides an excellent long-term survival advantage. S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Won, Kwon, Whi-An, Nguyen, La Ngoc Thu, Phan, Do Thanh Truc, Seo, Ho Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953905/ https://www.ncbi.nlm.nih.gov/pubmed/36831665 http://dx.doi.org/10.3390/cancers15041323

Ejemplares similares

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Novel G9a/DNMT first-in-class dual reversible inhibitor has potent antitumor effect in bladder cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
por: Baird, Bryce, et al.
Publicado: (2023)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature
por: Wu, Jie, et al.
Publicado: (2022)

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts
por: Tse, Jennifer, et al.
Publicado: (2019)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience
por: Nguyen, Thanh-Tuan, et al.
Publicado: (2018)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for upper tract urothelial carcinoma
por: Kim, Do Kyung, et al.
Publicado: (2020)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Animal Model of Interstitial Cystitis/Bladder Pain Syndrome
por: Kwon, Whi-An
Publicado: (2018)

Corrigendum to ‘Adult-onset mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome with progressive sensorineural hearing loss: A case report [Radiology Case Reports 16 (2021) 1865-1869]
por: Tong, Trang Mai, et al.
Publicado: (2021)

Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer
por: Kim, YongHwan, et al.
Publicado: (2023)

Validity of Machine Learning in Detecting Complicated Appendicitis in a Resource-Limited Setting: Findings from Vietnam
por: Phan-Mai, Tuong-Anh, et al.
Publicado: (2023)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Pyeloduodenal fistula complicating neoadjuvant chemotherapy in a patient diagnosed with muscle invasive bladder cancer
por: Alanee, Shaheen
Publicado: (2019)

Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Hepburn, Anastasia C., et al.
Publicado: (2021)

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
por: Beije, N., et al.
Publicado: (2022)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
por: D'Andrea, David, et al.
Publicado: (2022)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression
por: Seo, Ho Kyung, et al.
Publicado: (2016)

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
por: Cowan, N. G., et al.
Publicado: (2014)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fdtthqdp53c52bnds94df4l3tc